Franck Maizaud, Marc Labriffe, Hamza Sayadi, Stéphanie Belaiche, Pierre Marquet, Jean-Baptiste Woillard, Caroline Monchaud
{"title":"Renal Function–Guided Valganciclovir Dosing and Ganciclovir Exposure Variability: A Population Pharmacokinetic Simulation Study","authors":"Franck Maizaud, Marc Labriffe, Hamza Sayadi, Stéphanie Belaiche, Pierre Marquet, Jean-Baptiste Woillard, Caroline Monchaud","doi":"10.1111/bcpt.70329","DOIUrl":"10.1111/bcpt.70329","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ganciclovir (GCV) exposure after standard valganciclovir (VGCV) prophylaxis is highly variable. Guidelines recommend Cockcroft–Gault for renal dose adjustment. We evaluated whether Cockcroft–Gault-based dosing achieves the target prophylactic exposure (AUC<sub>0-24h:</sub> 40–60 mg.h/L) and whether MDRD or CKD-EPI alters exposure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using a validated population pharmacokinetic model, we simulated 10 000 adult solid organ transplant recipients. VGCV doses were assigned according to SmPC renal function categories based on Cockcroft–Gault, MDRD or CKD-EPI. Patient reclassification, target attainment and exposure around dosing thresholds (25, 40 and 60 mL/min) were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>MDRD and CKD-EPI reclassified 45.1% and 39.9% of patients, mostly downward, lowering target attainment (20.1% and 22.7% vs. 30.8% with Cockcroft–Gault). Target attainment never exceeded 40% in any category, and underexposure predominated, reaching up to 94.1% in the most impaired renal function categories. Target attainment was consistently lower just below each threshold, and the 25 and 40 mL/min thresholds were set above the renal function ranges where the corresponding regimens achieved target exposure.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Renal function category-based VGCV dosing does not reliably achieve target GCV exposure. Current thresholds are poorly aligned with the exposure-response relationship and warrant re-examination. Alternative equations do not reduce the variability, supporting exposure-guided approaches such as therapeutic drug monitoring and model-informed precision dosing.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 6","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149340453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Community Pharmacists' Perspectives and Experiences of Deprescribing in Québec, Canada: Findings From a Survey","authors":"Alexandre Campeau Calfat, Béatrice Martin, Caroline Sirois","doi":"10.1111/bcpt.70328","DOIUrl":"10.1111/bcpt.70328","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Community pharmacists in Quebec can bill for deprescribing. However, uptake remains low. We aimed to explore how community pharmacists perceive and engage in deprescribing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Community pharmacists were invited to complete an online survey through a pharmacists' social media group and a newsletter. Data were analysed using descriptive statistics and univariate chi-square tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 366 respondents, most were women (<i>n</i> = 269; 74%), worked full-time (<i>n</i> = 282; 77%), had time for clinical interventions (<i>n</i> = 223; 61%), while 53% (<i>n</i> = 193) had fewer than 11 years of experience. Three quarters (<i>n</i> = 271) reported initiating deprescribing at least monthly. Side effects (<i>n</i> = 273; 75%) and patients' requests (<i>n</i> = 220; 60%) were more common reasons for deprescribing. More than 70% (<i>n</i> = 268) reported that prescribers usually accepted recommendations. Initial and follow-up consultations were systematically billed by 50% (<i>n</i> = 183) and 48% (<i>n</i> = 174) of respondents, respectively. Deprescribing interventions and billing practices were more common among pharmacists with dedicated clinical time and those working full time (all <i>p</i> < 0.01). Main barriers to billing were insufficient training (<i>n</i> = 217; 59%), uncertainty about reimbursement eligibility (<i>n</i> = 127; 35%) and lack of time (<i>n</i> = 112; 31%). Integrated software was the most common facilitator (<i>n</i> = 246; 67%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Deprescribing was commonly reported among respondents and was often prompted by clinical concerns and patient requests. Billing uncertainties and time constraints remained important barriers, highlighting opportunities to better support deprescribing in community pharmacy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 6","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70328","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149294366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ben Tore Henriksen, Ulrika Gillespie, Liv Mathiesen, Yvonne Andersson
{"title":"The Patient Perspectives of Clinical Pharmacist Services in Hospitals and Clinics: A Focused Narrative Review of Qualitative Studies","authors":"Ben Tore Henriksen, Ulrika Gillespie, Liv Mathiesen, Yvonne Andersson","doi":"10.1111/bcpt.70327","DOIUrl":"10.1111/bcpt.70327","url":null,"abstract":"<p>Patient perspectives are highly important to ensure optimal patient care in hospitals or primary care settings. Clinical pharmacy services, in which clinical pharmacists provide direct patient care, are a relatively recent addition to healthcare and are increasing in scope and availability. In this focused narrative review, relevant qualitative studies describing patients' perspectives after the integration of clinical pharmacists into healthcare services were included. Patients described predominantly positive feedback, presented as facilitators. The facilitators described in studies were that patients <i>felt safe</i>, experienced <i>clear communication and collaboration</i> with pharmacists, <i>increased their knowledge</i> of medications, and appreciated pharmacists' <i>time and availability</i>. Occasionally, patients described challenges with the pharmacist or service, presented as barriers. The barriers were that patients were <i>unfamiliar with the clinical pharmacists' role and services</i>, <i>lacked trust or experienced conflicting information</i>, experienced a <i>lack of patient-centredness</i>, and some <i>disagreed or had challenges with elements of the intervention</i>. In conclusion, most perspectives represented positive facilitators that should be kept and protected in the future, with some barriers that can be overcome in the future for optimal patient care and development of clinical pharmacy services.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 6","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70327","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149294376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mahdis Nabipour, Charlotte Hagen Skadhauge, Line Juel Rasmussen, Hans Bräuner-Osborne, Jesper M. Mathiesen, Anders A. Jensen
{"title":"Peptide-Linked Bivalent Nanobody Constructs as Positive Allosteric Modulators of the Calcium-Sensing Receptor","authors":"Mahdis Nabipour, Charlotte Hagen Skadhauge, Line Juel Rasmussen, Hans Bräuner-Osborne, Jesper M. Mathiesen, Anders A. Jensen","doi":"10.1111/bcpt.70320","DOIUrl":"10.1111/bcpt.70320","url":null,"abstract":"<p>We previously developed nanobodies acting as positive allosteric modulators (PAMs) of the calcium-sensing receptor (CaSR). Here, we sought to develop more potent CaSR modulators by creating bivalent nanobody constructs using ‘tail-to-head’ peptide-linker conjugation. The constructs were functionally characterized at CaSR in HEK293 cells in a Ca<sup>2+</sup> mobilization assay. Homobivalent Nb4-Nb4 and Nb10-Nb10 constructs with linkers comprising 3, 5, 6 or 9 GGGG(S/T) repeats all displayed CaSR PAM potencies comparable with those exhibited by their monovalent counterparts. Likewise, five heterobivalent nanobodies combining Nb4, Nb10, Nb11, Nb36 or Nb37 through [GGGG(S/T)]<sub>9</sub> linkers exhibited PAM potencies similar to that of the monovalent version of the first (N-terminal) nanobody in the respective constructs. This prompted us to examine the functional properties of [GGGG(S/T)]<sub>9</sub>-linked constructs combining Nb4 and the mGluR5-selective nanobody PAM Nb43<sup>mGlu5</sup>. Nb4-L9-Nb43<sup>mGlu5</sup> displayed slightly increased CaSR PAM potency relative to Nb4, whereas Nb43<sup>mGlu5</sup>-L9-Nb4 exhibited ~40- and ~10-fold reduced potency compared with Nb4-L9-Nb43<sup>mGlu5</sup> and Nb4, respectively. The findings indicate that ‘tail-to-head’ conjugation markedly reduces CaSR binding affinity of the second (C-terminal) nanobody and likely explains the lack of synergistic enhancement of PAM potency in the bivalent constructs. Thus, the suitability of tail-to-head linker conjugation of nanobodies is context dependent, governed by how the nanobody engages its target and by whether the linker perturbs these interactions.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 6","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13716545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149285099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Usana Chatturong, Krongkarn Chootip, M. Paul Gleeson, Guntur Guntur, Yasuteru Shigeta, Kowit Hengphasatporn, Perle Totoson, Céline Demougeot
{"title":"3-[[4-(Benzylamino)quinazolin-2-yl] Amino] Benzenesulfonamide, a Quinazoline-Based PDE5 Inhibitor, Induces Vasorelaxation in Rat Mesenteric Arteries via Multiple Mechanisms","authors":"Usana Chatturong, Krongkarn Chootip, M. Paul Gleeson, Guntur Guntur, Yasuteru Shigeta, Kowit Hengphasatporn, Perle Totoson, Céline Demougeot","doi":"10.1111/bcpt.70324","DOIUrl":"10.1111/bcpt.70324","url":null,"abstract":"<div>\u0000 \u0000 <p>We synthesised a series of <i>N</i><sup>2</sup>,<i>N</i><sup>4</sup>-diaminoquinazoline derivatives, among which 3-[[4-(benzylamino)quinazolin-2-yl]amino]benzenesulfonamide (compound <b>5</b>) exhibited potent phosphodiesterase type 5 (PDE5) inhibitory activity. Increasing evidence suggests that PDE5 inhibition is a promising therapeutic strategy for peripheral vascular disease. This study aimed to investigate vasorelaxant effects of <b>5</b> and its underlying mechanisms in rat mesenteric arteries. Compound <b>5</b> was synthesised and purified, and evaluated its vascular activity using organ bath assay. Molecular docking was performed to identify its potential molecular targets. Compound <b>5</b> (0.0001–30 μM) induced relaxation of phenylephrine (PE)-precontracted mesenteric arteries (EC<sub>50</sub> = 0.76 ± 0.29 μM; <i>E</i><sub>max</sub> = 95.6% ± 1.1%). This effect was attenuated by endothelium removal (EC<sub>50</sub> = 5.24 ± 0.98 μM) and by L-NAME (eNOS inhibitor). Compound <b>5</b> enhanced sodium nitroprusside–induced relaxation, supporting modulation of the NO–sGC–cGMP axis via PDE5 inhibition. Iberiotoxin (BK<sub>Ca</sub> blocker) reduced relaxation, whereas 4-aminopyridine (K<sub>V</sub> blocker) and glibenclamide (K<sub>ATP</sub> blocker) had no effect. Compound <b>5</b> inhibited vasoconstriction mediated by extracellular Ca<sup>2+</sup> influx via receptor-operated Ca<sup>2+</sup> channels (ROCCs) and α<sub>1</sub>-adrenergic receptor activation. Molecular docking provided qualitative support for PDE5A, BK<sub>Ca</sub> channels and α<sub>1</sub>-adrenergic receptor as potential targets. In conclusion, <b>5</b> induces potent vasorelaxation in resistance arteries through eNOS/NO/cGMP signalling, BK<sub>Ca</sub> channel activation and inhibition of ROCCs and α<sub>1</sub>-adrenergic receptors, supporting its potential as a therapeutic candidate for peripheral vascular disorders.</p>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Stereoselective Determination of Omeprazole and 5-Hydroxy-Omeprazole in Dried Blood Spots for CYP2C19 Activity Assessment","authors":"Toon Hectors, Kenza Abouir, Emmanuel Varesio, Martijn L. Manson, Youssef Daali, Caroline Samer","doi":"10.1111/bcpt.70326","DOIUrl":"10.1111/bcpt.70326","url":null,"abstract":"<p>We previously proposed stereoselective 5-hydroxy-omeprazole/omeprazole cut-offs for R- and S-omeprazole to differentiate between rapid, normal, and poor CYP2C19 metabolisers. However, the performance of these stereoselective CYP2C19 phenotyping approaches has never been compared with conventional racemic omeprazole phenotyping. Therefore, dried blood spots from healthy, genetically predicted rapid (<i>n</i> = 15), normal (<i>n</i> = 15), and intermediate (<i>n</i> = 14) CYP2C19 metabolisers were stereoselectively reanalysed after administration of omeprazole alone (10 mg) and following CYP2C19 inhibition with voriconazole (400 mg administered prior to omeprazole). Using stereoselective R-, S-, and racemic 5-hydroxy-omeprazole/omeprazole ratios, CYP2C19 phenotyping performance was assessed by genotype–phenotype concordance and phenoconversion patterns relative to prior reports. An adaptive phenotyping strategy using the 3-h metabolic ratio in individuals with delayed absorption and retaining the 2-h ratio otherwise improved agreement with AUC-based CYP2C19 activity measures (Spearman ρ = 0.99 vs. 0.93 and 0.88 for fixed 2- and 3-h ratios, respectively). Across methods, the racemic approach demonstrated the most favourable overall performance, closely followed by the S-enantiomer–based strategy. In conclusion, while racemic omeprazole phenotyping modestly remains the most accurate strategy for assessing CYP2C19 activity, stereoselective assessment of the S-enantiomer provides an alternative that enables CYP2C19 phenotyping in patients treated with esomeprazole without treatment interruption or substitution with omeprazole.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70326","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hyun Woo Lee, Seungyeon Kim, Byoung Seok Ye, Yun Mi Yu
{"title":"Angiotensin II Receptor Blockers and the Risk of Alzheimer's Disease Progression: A Population-Based Cohort Study","authors":"Hyun Woo Lee, Seungyeon Kim, Byoung Seok Ye, Yun Mi Yu","doi":"10.1111/bcpt.70323","DOIUrl":"10.1111/bcpt.70323","url":null,"abstract":"<div>\u0000 \u0000 <p>We investigated the effects of angiotensin II receptor blockers (ARBs) on the progression of Alzheimer's disease (AD). This retrospective cohort study used data from the Korean nationwide claims data to identify patients with AD aged 60–79 years in 2010. ARB users and nonusers were 1:1 propensity score matched. Cox proportional hazards regression evaluated AD progression, defined as memantine initiation and mortality. Active-comparator and dose–response analyses were conducted. ARB use was associated with lower risks of memantine initiation (hazard ratio [HR] = 0.79; 95% confidence interval [CI] = 0.70–0.89) and mortality (HR = 0.83; 95% CI = 0.76–0.89). Cumulative exposure analyses showed stronger associations in the highest exposure categories, including 2–3 years of ARB use and ≥ 2 DDD-years, whereas associations in the lower exposure categories were not statistically significant. In active-comparator analyses, ARBs were associated with lower mortality risk than ACE inhibitors and beta-blockers, but not with dihydropyridine calcium channel blockers (CCBs). ARB use may be a reasonable antihypertensive choice in patients with AD, although the comparable outcomes between ARBs and CCBs suggest that these associations may not be unique to ARBs and may instead reflect shared blood pressure–lowering and vascular effects. Further prospective research is warranted to optimize antihypertensive selection in patients with AD.</p>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149226879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Telepharmacological Consultation for Polypharmacy Management in Primary Care: A Qualitative Study of General Practitioners' Experiences With Cross-Sectoral Coordination","authors":"Daniel Pilsgaard Henriksen","doi":"10.1111/bcpt.70325","DOIUrl":"10.1111/bcpt.70325","url":null,"abstract":"<p>The telepharmacological outpatient clinic (TPOC) is a hospital service in which clinical pharmacologists and clinical pharmacists review a patient's full medication regimen and hospital record, then discuss it with the referring general practitioner (GP) by video conference. Seven GPs in the Region of Southern Denmark who had used or been introduced to the service were interviewed to explore how it was used and what prevented wider use. Interviews were semi-structured and analysed thematically. GPs described practices organised around single diagnoses, with no separate pathway for patients who are difficult because they are complex. This was the setting the service entered. Four themes were identified. Whether the service was used depended on integration into existing clinical software. Its value reached past the referred patient, as GPs applied what they had learned to patients never referred. GPs described a coordination gap for patients attending several outpatient clinics, where no clinician held an overview of the whole treatment. They wanted the intensity of the service matched to the complexity of the case. GPs who wanted to refer more often pointed to awareness and time pressure, not to doubts about the service. Uptake appears to depend on workflow integration.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70325","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Min Jung Geum, Jinyoung Jeon, JinYoung Moon, Hyun Woo Lee, Soyun Kim, Yun Mi Yu, Young-Mi Ah
{"title":"Evidence on Glutathione and Boosters for Prevention of Chemotherapy-Induced Neuropathy: A Systematic Review and Network Meta-Analysis","authors":"Min Jung Geum, Jinyoung Jeon, JinYoung Moon, Hyun Woo Lee, Soyun Kim, Yun Mi Yu, Young-Mi Ah","doi":"10.1111/bcpt.70319","DOIUrl":"10.1111/bcpt.70319","url":null,"abstract":"<div>\u0000 \u0000 <p>Chemotherapy-induced peripheral neuropathy (CIPN) adversely affects treatment efficacy and quality of life. Despite studies on glutathione (GSH) or GSH boosters' antioxidative effects for prevention, optimal management remains uncertain. We conducted a systematic review and network meta-analysis of randomized controlled trials to consolidate and critically appraise the current evidence and to compare the efficacy of GSH and GSH boosters for the prevention of CIPN. The MEDLINE, Embase and CENTRAL databases were searched through March 2025. Twenty-five RCTs involving 1625 patients were included. No intervention significantly reduced all-grade CIPN compared with placebo. <i>N</i>-acetylcysteine (odds ratio [OR] 0.19, 95% credible intervals [CrI] 0.05–0.63), GSH (OR 0.34, 95% CrI 0.13–0.79) and vitamin E (OR 0.33, 95% CrI 0.11–0.91) were associated with a reduced incidence of grade 3/4 CIPN compared with placebo. <i>N</i>-acetylcysteine ranked highest for both all-grade and grade 3/4 CIPN prevention. These findings remained consistent in sensitivity analyses excluding patients with pre-existing neuropathy but were not retained in analyses restricted to double-blind studies. Overall, <i>N</i>-acetylcysteine, GSH, and vitamin E were associated with potential reductions in severe CIPN, with <i>N</i>-acetylcysteine consistently ranking highest, although these associations should be regarded as preliminary. Further rigorously conducted and adequately powered trials are warranted to confirm these findings and evaluate agents demonstrating potential benefits.</p>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149179150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hedda Skogum Riise, Melanie Simpson, Ketil Arne Espnes, Erling Andreas Tronvik, Andreas Kattem Husøy, Lise R. Øie, Anker Stubberud, Emil Kofoed, Aurora Harsvik Alstad, Hedda Hoff Hagen, Maren Guldteig Lien, Marie Larsen Stavseng, Ella Rian Sæther, Tore Wergeland
{"title":"Serum Concentration Relationships of Candesartan in Migraine Prevention","authors":"Hedda Skogum Riise, Melanie Simpson, Ketil Arne Espnes, Erling Andreas Tronvik, Andreas Kattem Husøy, Lise R. Øie, Anker Stubberud, Emil Kofoed, Aurora Harsvik Alstad, Hedda Hoff Hagen, Maren Guldteig Lien, Marie Larsen Stavseng, Ella Rian Sæther, Tore Wergeland","doi":"10.1111/bcpt.70322","DOIUrl":"10.1111/bcpt.70322","url":null,"abstract":"<p>Migraine is a common disabling disorder, and optimising affordable preventive treatments remains highly relevant. Candesartan is an effective and well-tolerated preventive treatment, but little is known about its dose-concentration–response relationships. We explored these relationships using data from the MigriNor study, a prospective observational cohort of adults with episodic or chronic migraine initiating oral preventive treatment. A total of 166 participants using candesartan were included (median age 35 years; 89% female). Participants completed a daily electronic headache diary during a 4-week baseline and 12-week follow-up period with accompanying blood sampling. Dosing regimen was flexible. No differences in adverse drug reactions (ADRs) or treatment acceptability were observed between participants starting 4 versus 8 mg. Substantial interindividual variability in serum concentrations was observed. Higher serum concentrations were associated with lower odds of headache attacks (OR = 0.97, 95% CI = 0.96–0.98, <i>p</i> < 0.001) and migraine attacks (OR = 0.98, 95% CI = 0.97–0.99, <i>p</i> = 0.005). Interquartile ranges of serum concentrations among ≥ 30% and ≥ 50% responders were 62.9–141.2 and 62.3–129.3 nmol/L, respectively, suggesting preliminary therapeutic reference ranges. Serum concentration was not associated with ADRs or treatment acceptability. Interpretation is limited by the flexible dosing design, and studies with fixed dosing regimens are warranted.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"139 5","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13657683/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149164326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}